AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3619096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.3 mg epinephrine (Group 4)
Number of subjects: 96
Study 3619096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.4 mg epinephrine (Group 5)
Number of subjects: 96
Study 3619096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.5 mg epinephrine (Group 6)
Number of subjects: 96
Study 3619096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus increasing dosages of epinephrine (Groups 2-6)
Number of subjects: 96
Study 30719932 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 20
Study 30719932 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion
Number of subjects: 20
Study 27584137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-activity foot (LA)
Number of subjects: 28
Study 27584137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-activity energy-storage-and-return (ESAR) foot
Number of subjects: 28
Study 26412178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 36
Study 26412178 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume hemofiltration (SVHF)
Number of subjects: 36
Study 22791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and Irinotecan
Number of subjects: 0
Study 22791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib alone
Number of subjects: 0
Study 22791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan added at time of progression on bortezomib
Number of subjects: 0
Study 21054506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Conditioner (TC)
Number of subjects: 44
Study 21054506 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopolymerising Hard Reline Material (AHRM)
Number of subjects: 44
Study 19117033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium (3 g/day) plus vitamin D (1 mg/day) (Group A, n=49)
Number of subjects: 197
Study 19117033 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone (Group B, n=49)
Number of subjects: 197
Study 19117033 — intervention group
Group type: COMPARATOR
Intervention: No supplements (Group C, n=50)
Number of subjects: 197
Study 17522475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) low dose (50 mg/week)
Number of subjects: 54
Study 17522475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) medium dose (100 mg/week)
Number of subjects: 54
Study 17522475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) high dose (200 mg/week)
Number of subjects: 54
Study 17522475 — intervention group
Group type: COMPARATOR
Intervention: Control (non-randomized)
Number of subjects: 54
Study 15333268 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific language screening conducted at 18 and 24 months
Number of subjects: 10355
Study 15333268 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10355
Study 12193356 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment in a clinical trial
Number of subjects: 54
Study 12193356 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment if shown effective
Number of subjects: 54
Study 12193356 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to enter the planned trial
Number of subjects: 54
Study 12193356 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised trial materials
Number of subjects: 54
Study 9539641 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald's Quarter Pounder, french fries, and chocolate shake
Number of subjects: 0
Study 9539641 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald's Sausage Biscuit with Egg, cheese, raw onion, and chocolate milk
Number of subjects: 0
Study 9539641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wendy's Chili and red wine
Number of subjects: 0
Study 7973772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/5-fluorouracil/leucovorin (PFL) combination
Number of subjects: 16
Study 7973772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine) added to PFL
Number of subjects: 16
Study 7973772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at 20 mg/m2/d
Number of subjects: 16
Study 7973772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at 25 mg/m2/d
Number of subjects: 16
Study 2700878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (O.C.)
Number of subjects: 1044
Study 2700878 — intervention group
Group type: COMPARATOR
Intervention: Control (non-O.C. users)
Number of subjects: 1044
Study 786260 — intervention group
Group type: EXPERIMENTAL
Intervention: PLP 100‐127
Number of subjects: 30
Study 786260 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 30
Study 31580800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget therapy
Number of subjects: 11
Study 31580800 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 11
Study 28382797 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 343
Study 28382797 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 343
Study 25790066 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxaemia induced by lipopolysaccharide (LPS) 0.3 ng/kg b.w. at 12:00 h (day visit)
Number of subjects: 12
Study 25790066 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxaemia induced by lipopolysaccharide (LPS) 0.3 ng/kg b.w. at 24:00 h (night visit)
Number of subjects: 12
Study 23053123 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for 6 weeks
Number of subjects: 13
Study 23053123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 13
Study 21150602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF) and melphalan based isolated limb perfusion (TM-ILP)
Number of subjects: 0
Study 21150602 — intervention group
Group type: COMPARATOR
Intervention: Melphalan only based isolated limb perfusion (M-ILP)
Number of subjects: 0
Study 21150602 — intervention group
Group type: COMPARATOR
Intervention: Isolated limb infusion (ILI) with melphalan and actinimycin D
Number of subjects: 0
Study 19567091 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160
Study 19567091 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160
Study 19567091 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160
Study 19567091 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160
Study 16389160 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 62
Study 16389160 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 62
Study 16389160 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril plus Losartan (20 mg/day + 100 mg/day)
Number of subjects: 62
Study 15285927 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I (144 Gy, TG-43)
Number of subjects: 122
Study 15285927 — intervention group
Group type: EXPERIMENTAL
Intervention: (103)Pd (125 Gy, NIST-99)
Number of subjects: 122
Study 15285927 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I
Number of subjects: 122
Study 15285927 — intervention group
Group type: EXPERIMENTAL
Intervention: (103)Pd
Number of subjects: 122
Study 15285927 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I and (103)Pd
Number of subjects: 122
Study 11070965 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive intravenous morphine (0.15 mg.kg‐1)
Number of subjects: 60
Study 11070965 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural morphine (75 micrograms.kg‐1)
Number of subjects: 60
Study 11070965 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous saline)
Number of subjects: 60
Study 9061114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of vecuronium administered 5 minutes prior to inflation of a pneumatic tourniquet (Group I)
Number of subjects: 16
Study 9061114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of vecuronium administered after inflation of the tourniquet (Group II)
Number of subjects: 16
Study 9061114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 30‐40 micrograms/kg i.v. administered to all subjects in both groups
Number of subjects: 16
Study 8112641 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure including subcutaneous retention sutures
Number of subjects: 80
Study 8112641 — intervention group
Group type: COMPARATOR
Intervention: Standard wound closure
Number of subjects: 80
Study 31583603 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger boy (ages 12, 15)
Number of subjects: 360
Study 31583603 — intervention group
Group type: EXPERIMENTAL
Intervention: Older man (ages 18, 21, 24)
Number of subjects: 360
Study 31583603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers
Number of subjects: 360
Study 31583603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers
Number of subjects: 360
Study 29783674 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean male smokers
Number of subjects: 300
Study 29783674 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean smokers
Number of subjects: 300
Study 27128564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 801
Study 27128564 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 801
Study 24452645 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20
Study 24452645 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Cortex Stimulation (MCS)
Number of subjects: 20
Study 24452645 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative rTMS
Number of subjects: 20
Study 21349756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pédimed(®) cream applied twice daily for 4 weeks
Number of subjects: 54
Study 21349756 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 54
Study 21349756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pédimed(®) cream
Number of subjects: 54
Study 21349756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15932664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (0.075 ml/10 kg)
Number of subjects: 98
Study 12172535 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin G (2.4 million units, intramuscular injection)
Number of subjects: 60
Study 9744373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% twice daily
Number of subjects: 572
Study 9744373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% three times daily
Number of subjects: 572
Study 9744373 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2.0% three times daily
Number of subjects: 572
Study 9744373 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 572
Study 9744373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% (twice daily)
Number of subjects: 572
Study 9744373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% (three times daily)
Number of subjects: 572
Study 9744373 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide
Number of subjects: 572
Study 7544184 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 17
Study 7544184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen season
Number of subjects: 17
Study 7544184 — intervention group
Group type: COMPARATOR
Intervention: Control group (before immunotherapy)
Number of subjects: 17
Study 2754576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily plus parent simulation of diabetes (MF + S)
Number of subjects: 32
Study 2754576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily (MF)
Number of subjects: 32
Study 2754576 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller family groups (part of MF or MF + S)
Number of subjects: 32
Study 2754576 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study 869668 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (various doses)
Number of subjects: 0
Study 29128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (6×10^9 CFU/day)
Number of subjects: 95
Study 29128317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 27982269 — intervention group
Group type: EXPERIMENTAL
Intervention: ReHOT clinical trial participation
Number of subjects: 109
Study 26302034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yoghurt supplemented with 80 mg d(‐1) of rooster comb extract (RCE)
Number of subjects: 40
Study 26302034 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (same yoghurt without RCE)
Number of subjects: 40
Study 24041934 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage nursing assessment and intervention after discharge and at follow-up
Number of subjects: 271
Study 24041934 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 271
Study 20473703 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 questionnaire
Number of subjects: 0
Study 20473703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping from QLQ-C30 to EQ-5D
Number of subjects: 0
Study 18262688 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cornstarch pudding (25g carbohydrate in 150g water)
Number of subjects: 8
Study 18262688 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cornstarch stew (25g carbohydrate in 300g water)
Number of subjects: 8
Study 18262688 — intervention group
Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 8
Study 16647404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate therapy
Number of subjects: 59
Study 16647404 — intervention group
Group type: COMPARATOR
Intervention: Control (patients who had not received pamidronate)
Number of subjects: 59
Study 14659383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology social workers
Number of subjects: 0
Study 14659383 — intervention group
Group type: COMPARATOR
Intervention: Oncology physicians
Number of subjects: 0
Study 14659383 — intervention group
Group type: COMPARATOR
Intervention: Oncology nurses
Number of subjects: 0
Study 10824468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (100 mg/kg body wt) intravenously slowly soon after anaesthetic induction, followed by 100 mg/kg in the cardiopulmonary bypass pump and 100 mg/kg after weaning from bypass over a period of 3 h
Number of subjects: 170
Study 10824468 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as placebo (control group)
Number of subjects: 170
Study 10824468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 170
Study 9035702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene
Number of subjects: 0
Study 9035702 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily treatment of Tazarotene
Number of subjects: 0
Study 1627203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 1% cream applied twice a day for 4 weeks
Number of subjects: 21
Study 1627203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream applied twice a day for 4 weeks
Number of subjects: 21
Study 6148959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 8
Study 6148959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 40 mg
Number of subjects: 8
Study 6148959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 8
Study 6148959 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8
Study 6148959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30882595 — intervention group
Group type: COMPARATOR
Intervention: Consumption of at least five servings per week of fish
Number of subjects: 12279
Study 30882595 — intervention group
Group type: COMPARATOR
Intervention: Highest quintile of omega-3 fatty acid intake
Number of subjects: 12279
Study 29105259 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification Tree Analysis (CTA)
Number of subjects: 0
Study 29105259 — intervention group
Group type: COMPARATOR
Intervention: Structural Equation Models (SEMs)
Number of subjects: 0
Study 27311311 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (2% CHX-a)
Number of subjects: 3682
Study 27311311 — intervention group
Group type: EXPERIMENTAL
Intervention: <1% chlorhexidine (<1% CHX-a)
Number of subjects: 3682
Study 27311311 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (PVI)
Number of subjects: 3682
Study 27311311 — intervention group
Group type: COMPARATOR
Intervention: Other antiseptics
Number of subjects: 3682
Study 24925722 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors (mostly but not entirely)
Number of subjects: 159
Study 24925722 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 159
Study 22465578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirasol‐inactivated fresh frozen plasma (FFP)
Number of subjects: 60
Study 22465578 — intervention group
Group type: COMPARATOR
Intervention: noninactivated fresh frozen plasma (FFP)
Number of subjects: 60
Study 20718287 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings of betrayal by the UNHCR
Number of subjects: 22
Study 18039351 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 79‐4980 (13 or 22 mg kg(‐1) pegylated liposomes)
Number of subjects: 26
Study 18039351 — intervention group
Group type: COMPARATOR
Intervention: Standard rFVIII‐FS (35 IU kg(‐1))
Number of subjects: 26
Study 16200601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 24 weeks
Number of subjects: 313
Study 16200601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 16200601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 313
Study 14612278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle manoeuvre
Number of subjects: 131
Study 14612278 — intervention group
Group type: COMPARATOR
Intervention: Control (without Pringle manoeuvre)
Number of subjects: 131
Study 10088982 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 225
Study 10088982 — intervention group
Group type: COMPARATOR
Intervention: Frustration
Number of subjects: 225
Study 10088982 — intervention group
Group type: COMPARATOR
Intervention: Harassment
Number of subjects: 225
Study 10088982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low educational level
Number of subjects: 225
Study 7555033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 capsule twice daily (A)
Number of subjects: 21
Study 7555033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 capsules in the morning and 1 in the evening (B)
Number of subjects: 21
Study 7555033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 capsules twice daily (C)
Number of subjects: 21
Study 2258450 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine 400 mg
Number of subjects: 92
Study 2258450 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 300 mg
Number of subjects: 92
Study 2258450 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine and Amitriptyline
Number of subjects: 92
Study 7008475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (LDH)
Number of subjects: 2
Study 31900193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery prizes based on timely clinic visits and demonstration of viral suppression (T1, n=110)
Number of subjects: 330
Study 31900193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery prizes conditional on high adherence measured by a medication event management system (MEMS) cap (T2, n=110)
Number of subjects: 330
Study 31900193 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care (Control, n=110)
Number of subjects: 330
Study 30539411 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR-cCTA (80 kV; automated-mAs; 60 mL of CM, 350 mgL/mL)
Number of subjects: 98
Study 30539411 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR-cCTA
Number of subjects: 98
Study 30539411 — intervention group
Group type: COMPARATOR
Intervention: iDose-cCTA
Number of subjects: 98
Study 27190943 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-CPP chewing gum
Number of subjects: 10
Study 27190943 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural chewable products (Tulsi, sesame seeds, fennel seeds, coconut)
Number of subjects: 10
Study 27190943 — intervention group
Group type: COMPARATOR
Intervention: Coconut group
Number of subjects: 10
Study 27190943 — intervention group
Group type: COMPARATOR
Intervention: Fennel group
Number of subjects: 10
Study 27190943 — intervention group
Group type: EXPERIMENTAL
Intervention: Recaldent (ACP-CPP)
Number of subjects: 10
Study 27190943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame group
Number of subjects: 10
Study 24350624 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with totally extraperitoneal endoscopic mesh placement
Number of subjects: 30
Study 24350624 — intervention group
Group type: COMPARATOR
Intervention: Normal MRI group (without BME)
Number of subjects: 30
Study 24471210 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of fatty fish
Number of subjects: 105
Study 21212768 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL-DEP (calorie deprived state, <10% of estimated energy requirements)
Number of subjects: 13
Study 21212768 — intervention group
Group type: COMPARATOR
Intervention: FED (fully fed state)
Number of subjects: 13
Study 19920416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 400 mg diluted in 20 mL
Number of subjects: 165
Study 19920416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 400 mg diluted in 30 mL
Number of subjects: 165
Study 19920416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 400 mg diluted in 40 mL
Number of subjects: 165